77145-61-0
77145-61-0
Chemical Structure
SR 57227A
- CAS No.: 77145-61-0
- Formula:C10H15Cl2N3
- Molecular Weight:248.15
IUPAC Name: 1-(6-chloropyridin-2-yl)piperidin-4-amine hydrochloride
InChIKey: FUMINTAAUJUVMP-UHFFFAOYSA-N
SMILES: ClC1=NC(N2CCC(N)CC2)=CC=C1.[H]Cl
Biological Activity: SR 57227A is a potent, orally active and selective 5-HT3 receptor agonist, with ability to cross the blood brain barrier. SR 57227A has affinities (IC50) varying between 2.8 and 250 nM for 5-HT3 receptor binding sites in rat cortical membranes and on whole NG 108-15 cells or their membranes. Anti-depressant effects[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SR 57227A | 99.86% | SR 57227A is a potent, orally active and selective 5-HT3 receptor agonist, with ability to cross the blood brain barrier. SR 57227A has affinities (IC50) varying between 2.8 and 250 nM for 5-HT3 receptor binding sites in rat cortical membranes and on whole NG 108-15 cells or their membranes. Anti-depressant effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SR 57227A (Standard) | ≥98% | SR 57227A (Standard) is the analytical standard of SR 57227A (HY-102064). This product is intended for research and analytical applications. SR 57227A is a potent, orally active and selective 5-HT3 receptor agonist, with ability to cross the blood brain barrier. SR 57227A has affinities (IC50) varying between 2.8 and 250 nM for 5-HT3 receptor binding sites in rat cortical membranes and on whole NG 108-15 cells or their membranes. Anti-depressant effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Poncelet M, et al, Le Fur G. Antidepressant-like effects of SR 57227A, a 5-HT3 receptor agonist, in rodents. J Neural Transm Gen Sect. 1995;102(2):83‐90. [Content Brief]
- [2]. Bachy A, et al. SR 57227A: a potent and selective agonist at central and peripheral 5-HT3 receptors in vitro and in vivo. Eur J Pharmacol. 1993;237(2-3):299‐309. [Content Brief]
